230 Abstracts ous data collection methods; to provide an interactive fo- rum for discussing recommendations for the use of each method; and to discuss the implications that alternative measurement strategies may have on reported results. PARTICIPANTS WHO WOULD BENEFIT: This ses- sion is directed at individuals who are responsible for the design and conduct of pharmacoeconomic evaluations. Individuals who need to interpret study results will also benefit from this workshop. Pharmacoeconomic studies are often designed without the appropriate concern for, or justification of, the data collection method used. Previous research has focused mainly on what data to collect rather than how to col- lect the data. This current research focuses on the issue of study validity through the use of various data collec- tion strategies. This workshop will discuss the appropri- ate application of each strategy and provide recommen- dations for the employment of particular data collection methods in the context of specific studies. Methodolo- gies to be discussed include office-based self-administra- tion, patient diaries, face-to-face interviews (written and oral), telephone interviews (personal and CATI), and postal surveys. The research presented here augments earlier research by informing researchers of potential is- sues with data collection techniques on resource utiliza- tion collection. WMQ1 THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM HEALTH QUESTIONNAIRE (SCAP-HQ): A BRIEF INSTRUMENT TO ASSESS OUTCOMES OF CARE IN SCHIZOPHRENIA Johnstone BM 1 , Loosbrock DL 1 , Lehman AF 2 , Fischer EP 3 , Postrado L 2 , Delahanty J 2 , Russo PA 4 1 Health Outcomes Evaluation Group, United States Medical Division, Eli Lilly and Company, Indianapolis, IN, USA; 2 Center for Mental Health Services Research, University of Maryland, Baltimore, MD, USA; 3 Center for Mental Healthcare Research, University of Arkansas for Medical Sciences, Little Rock, AR, USA, 4 The Medstat Group, Washington, DC, USA WORKSHOP OBJECTIVE: Advances in treatment for schizophrenia and the development of evidence-based standards of care demand better methods for population- based research on this disease and routine assessment of treatment outcomes in systems of care. The purpose of this workshop is to introduce the Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ), a brief instrument to measure the clinical and functional outcomes of care for schizophrenia. We will describe the rationale for the instrument, the process of its develop- ment, and its scope of measurement. We will discuss the validity of the SCAP-HQ in relation to concurrent ad- ministration of major clinical and functional instruments for schizophrenia. We will consider applications of SCAP-HQ in longitudinal studies and present results of its use in this context. The participant will understand potential appli- cations of the instrument in research and routine assess- ment. PARTICIPANTS WHO WOULD BENEFIT: Providers of care for schizophrenia and researchers with interest in methods to measure and monitor outcomes of treatment in actual care settings. Schizophrenia affects about one percent of the popula- tion and exacts substantial human and economic costs. We will discuss the development, validation, and applica- tions of a new instrument (SCAP-HQ) to assess out- comes of care for this disease in research or routine clini- cal assessment. We will address measurement of patients’ disease status (symptoms, side effects), generic health sta- tus, functional status (productivity, social relations, daily activities, leisure), quality of life, and safety and welfare. We will evaluate the instrument’s performance with re- spect to internal consistency, test-retest reliability, and criterion validity in comparison to existing instruments. We will discuss use of the instrument to model the effect of prior period clinical status, medication therapy, and other patient characteristics on clinical and functional outcome. Participants with interest in patient-centered methods for schizophrenia outcomes assessment will ben- efit from this workshop. SESSION 2 WPE4 AN ELECTRONIC TOOL FOR EMPIRIC ASSESSMENT OF DISEASE RISK, CATEGORIZATION OF PATIENTS AT RISK AND MONITORING OF OUTCOMES Ambegaonkar A, Day D, Brandman J, Livengood K, Lubowski TJ, Nobles-Knight D, Van Vleet J, Woon J, Yamaga C Clinical Pharmacy Outcomes Research, Pfizer Inc., New York, NY, USA WORKSHOP OBJECTIVE: The purpose of this work- shop is to present Multiple Disease Risk Assessment 2000 (MDRA 2000), a tool for empiric assessment of disease risk factors, categorization of patients at risk, and monitoring of patient outcomes. PARTICIPANTS WHO WOULD BENEFIT: Health- care decision-makers and others involved in the process of monitoring and evaluating patient outcomes. Identifying patients at risk for disease and providing ap- propriate care can improve patient outcomes and results in significant cost reductions to healthcare systems. Mul- tiple Disease Risk Assessment 2000 provides clinicians with a valuable tool for performing a systematic analysis of patients at risk of developing a selected disease, infec- tion, or medical complication. The tool can identify pres- ence of key risk factors, serve as a guideline for initiating a therapeutic intervention, and can help identify factors CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector